Amphix Bio today announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials and expand its pipeline to target additional neurological conditions. The funding comes from a syndicate of mission-driven investors dedicated to bringing new therapies into the clinic for conditions with high unmet need. This financing round brings the total dilutive and non-dilutive funds raised by the company to $18 million.

Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan - the length of time that people can live productive, fulfilling lives.